Nucleocapsid Antigenemia in Patients Receiving Anti-CD20 Therapy With Protracted COVID-19. (17th August 2022)

• Record Type: Journal Article
• Authors: Wilber, Eli; Piantadosi, Anne; Babiker, Ahmed; McLendon, Kaleb; O'Sick, William; Fitts, Eric; Webster, Andrew S; Verkerke, Hans; Kim, James S; Phadke, Varun K; Rouphael, Nadine; Titanji, Boghuma K; Blake, William T; Howard-Anderson, Jessica; Roback, John D; Lam, Wilbur A; Damhorst, Gregory L
• Is Part Of: Open forum infectious diseases. Volume 9:Number 8(2022)
• Publication Date: 2022-08-17
• Subjects: SARS-CoV-2 -- antigenemia -- diagnostics -- immunocompromised; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofac419
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Immunocompromised patients with prolonged coronavirus disease 2019 symptoms present diagnostic and therapeutic challenges. We measured viral nucleocapsid antigenemia in 3 patients treated with anti-CD20 immunotherapy who acquired severe acute respiratory syndrome coronavirus 2 infection and experienced protracted symptoms. Our results support nucleocapsid antigenemia as a marker of persistent infection and therapeutic response.